Idea Evolver’s Post

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers: Time for Drug Channels’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes the following 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB. You can find links to each company’s data below. When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2022. However, some companies had net price gains. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs at the biggest drugmakers to less than half of their list prices. For the eight companies with multiple years of data, the gross-to-net difference in price changes was the smallest gap in six years. See the second chart below. As I have noted, powerful industry forces may trigger the gross-to-net bubble to deflate. But for now, the 2022 data provide fresh inconvenient facts for the drug pricing flat earthers (#DPFE). Patient assistance funding accounts for a significant portion of gross-to-net differences. Learn about the future of these programs during my upcoming live video webinar, PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding, on June 23, 2023, from 12:00 p.m. to 1:30 p.m. ET. Click here to learn more and sign up. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only. #pbm #drugpricing #pharmaceutical

Pharmaceutical #rebates were a big part of the #PBM conversation in 2023 (as they should have been). But what are pharmaceutical rebates? Why do they matter? We covered these topics and more in one of our most read blogs: Ben Schuster answered the basic questions, explained how rebates dollars flow through the system, and dove into some of the deeper complications surrounding rebates (along with what #plansponsors can do to improve their PBM contracts). https://okt.to/gMs3Lr

Unveiling the 2023 Pharma 50 - our annual roundup of the 50 largest pharmaceutical companies globally, based on the latest revenue data. This year's overview of the industry’s leaders explore insights into the organizations driving the pharmaceutical world. These companies have exhibited significant resilience and innovation amidst pandemic challenges, with Pfizer leading the pack for the second year running. What trends do you anticipate seeing in the pharmaceutical industry in 2023? #Pharma50 #PharmaceuticalIndustry #HealthcareIndustry #Innovation #TopPharmaCompanies"

Pharmaceutical #rebates were a big part of the #PBM conversation in 2023 (as they should have been). But what are pharmaceutical rebates? Why do they matter? We covered these topics and more in one of our most read blogs: Ben Schuster answered the basic questions, explained how rebates dollars flow through the system, and dove into some of the deeper complications surrounding rebates (along with what #plansponsors can do to improve their PBM contracts). https://okt.to/6aOTtK

Novo Nordisk Initially Opposes, Then Joins CMS Drug Pricing Program Amid Industry Tensions Novo Nordisk has filed a lawsuit challenging the drug price negotiation provisions of the Inflation Reduction Act (IRA), citing First and Fifth Amendment concerns. The company's insulin products, accounting for $2.6 billion in Medicare Part D expenditures, fall under CMS price negotiations starting in 2026. Despite the lawsuit, Novo Nordisk intends to participate in the negotiation process by the October 1st deadline. Other pharmaceutical companies, including AstraZeneca, Johnson & Johnson, and Merck, have also raised legal challenges while agreeing to participate. If you're interested in continuing to read the full story and want to stay updated with the Latest Pharma News in USA, visit Pharmtales. #pharma #pharmaceutical #pharmtales #latestnews #pharmanewss #pharmaceuticalindustry #novonordisk #drugs #Inflationreductionact #pharmaceuticalcompany https://lnkd.in/dYgd-zmU

#drugs https://lnkd.in/gFyvDJtk As anticipated, there was a shakeup at the top of the #pharma #industry rankings in 2023. Having sat at the top of the pile for several years as a result of huge sales of its COVID-19 vaccine Comirnaty (tozinameran), Pfizer dropped precipitously from the top spot to be replaced by Johnson & Johnson (Fig. 1a). The new market leader grew prescription #pharmaceutical #sales by almost US$3 billion year on year, the largest absolute growth in the cohort and second largest in percentage terms. Johnson & Johnson’s growth is driven by a diversified mix of products, led by Darzelex (daratumumab) and Stelara (ustekinumab). Both of these products also feature in the top ten selling products in 2023 (Fig. 1b). Darzalex, indicated for multiple myeloma, climbs five positions from 14th in 2022 to 9th in 2023, and is the third biggest year-on-year growth driver among the top ten in percentage terms. This trajectory is expected to continue as Darzalex cements its position as the leader in an increasingly crowded multiple myeloma market. Stelara, on the other hand, could well be enjoying its last year in the top ten, with patent expiry opening up the door to biosimilar competition and forecasts projecting a rapid decline in sales for the product.

BRG reports that #pharma manufacturers have seen a 163% increase in 340B sales over the last five years, and "340B is on pace to be the largest federal drug program by 2027." But the complexity of the program keeps rising. Check out Kyle Forcier's three steps to help manage the 340B program successfully. Learn more in this Pharmaceutical Commerce Magazine article ⤵ #340B #pharmasales #pharmamanufacturing #lifesciences #revenuemanagement #revenueoptimization #thoughtleadership https://lnkd.in/ejTq744R

The Inflation Reduction Act is bringing significant changes to the pharmaceutical industry that will impact drug pricing, development, and market strategies. We outline three essential steps that pharmaceutical companies can take to secure a strong position in the coming months and years > https://owy.mn/46pFnUr #pharma #IRA #OWHealth

This insightful piece uncovers the latest #Pharma GTN trends —how the GTN landscape is evolving and its impact on pharmaceutical pricing strategies. 💡✨ #Pharmaceuticals

When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2022. Read this review of 10 top drug companies to see how and why the gross-to-net bubble is progressing this way. #Pharmaceuticals #PharmacyBenefits #SpecialtyDrugs #PBM #Truveris